Radu Codel
Cardiovascular Disease · Vero Beach, FLNPI 1821082827
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 351 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,821 and has fallen 95.9% since, to $74 in 2023.
Across 351 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$886
- AstraZeneca$699
- Sanofi-aventis U.S. LLC$561
- Boston Scientific$364
- Amarin Pharma, Inc.$353
- Novo Nordisk$344
- plus $2K from 17 others
What the payments were for
- Food & beverage$5,381100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 58 | $886 |
| AstraZeneca | 50 | $699 |
| Sanofi-aventis U.S. LLC | 33 | $561 |
| Boston Scientific | 9 | $364 |
| Amarin Pharma, Inc. | 22 | $353 |
| Novo Nordisk | 21 | $344 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $282 |
| Boehringer Ingelheim | 21 | $273 |
| Merck | 20 | $263 |
| E.r. Squibb & Sons, L.L.C. | 17 | $249 |
| Johnson & Johnson | 22 | $236 |
| Novartis | 13 | $207 |
| Kowa Pharmaceuticals America, Inc. | 14 | $201 |
| Bayer | 8 | $153 |
| Pfizer | 6 | $83 |
| Esperion Therapeutics, Inc. | 6 | $76 |
| GSK | 3 | $40 |
| Arbor Pharmaceuticals, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $30 |
| Abbott | 1 | $19 |
| Medicure Pharma Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$145
- Repatha$125
- Ozempic$122
- Watchman$110
- SOLIQUA 100/33$107
How this compares
$5,390 in reported general payments places this provider in the 65th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Vero Beach
- Vijay HaryaniVero Beach$413K
- Raghavendra Charan MakamVero Beach$110K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.